Funding Opportunities

Below is a curated list of funding opportunities that may be of interest to Cancer Center members. 

Ovarian Research Program (OCRP) Pre-Announcement

https://cdmrp.health.mil/pubs/press/2023/23ocrppreann

Sponsor: Department of Defense

Abstract: The FY23 Defense Appropriations Act provides funding for the Ovarian Cancer Research Program (OCRP) to support patient-centered research to prevent, detect, treat, and cure ovarian cancer to enhance the health and well-being of Service Members, Veterans, their family members, and all women impacted by this disease. The managing agent for the anticipated funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command (USAMRDC). The OCRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY23 funding opportunities.

Application Details: Pre-application and application deadlines will be available when the announcements are released

The NCI Transition Career Development Award (K22 - Independent Clinical Trial Required)

PAR-21-111

Sponsor: National Institute of Health (NIH); American Cancer Society (ACS)

Abstract: This Funding Opportunity Announcement (FOA) represents the continuation of an NCI program to facilitate the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions. This goal is achieved by providing protected time through salary and research support for the initial 3 years of the first independent tenure-track faculty position, or its equivalent, beginning at the time when the candidate starts a tenure-track faculty position.

Application Due Date: February 12, 2023, June 12, 2023

Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)

PAR-21-035

Sponsor: National Cancer Institute (NCI); United States Department of Health and Human Service (HHS)

Abstract: The purpose of this NOFO is to encourage new approaches to support therapeutic development in ultra-rare pediatric and adult cancers, including molecularly-defined subsets of more common cancers.

LOI Due Date: January 3, 2023

Application Due Date: February 27, 2023

Novel Approaches to support therapeutic development in ultra-rare cancers

RFA-FD-23-008

Sponsor: Department of Health and Human Services, Food and Drug Administration

Abstract: The purpose of this NOFO is to encourage new approaches to support therapeutic development in ultra-rare pediatric and adult cancers, including molecularly-defined subsets of more common cancers.

LOI Due Date: January 3, 2023

Application Due Date: February 27, 2023

Pilot and Exploratory Projects in Palliative Care of Cancer Patients and Their Families

RFA: Pilot and Exploratory Projects in Palliative Care of Cancer Patients and Their Families

Sponsor: American Cancer Society (ACS)

Abstract: The development of the specialty of palliative medicine is a critical step in addressing the unmet needs of patients with serious illness and their families.

Pilot data are typically needed before funding agencies (e.g., NIH, VA, or the American Cancer Society) will consider funding a research project. In an effort to support clinician investigators conducting patient-oriented research in palliative care, the American Cancer Society (ACS), in parallel with the National Palliative Care Research Center (NPCRC), is soliciting applications for pilot/exploratory research grants in palliative care for cancer patients and their families. These grants will generate the pilot data necessary to maximize an investigator's chances of successfully competing for larger grants.

Application Due Date: April 1, 2023

NCI Cancer Moonshot Scholars Diversity Program (CMSDP) (R01 Clinical Trial Optional)

RFA-CA-22-050

Sponsor: National Cancer Institute (NCI)

Abstract: This Funding Opportunity Announcement (FOA) supports the Cancer Moonshot Scholars Diversity Program (CMSDP) and solicits R01 grant applications that propose independent research projects within the scientific mission of the National Cancer Institute (NCI). The overarching goal of the CMSDP is to increase the number of R01 Early Stage Investigators (ESIs) and enhance the diversity of the cancer research workforce while promoting scientific advancements in cancer. Investigators from diverse backgrounds, including those from underrepresented groups (NOT-OD-20-031, Notice of NIH’s Interest in Diversity), are encouraged to work with their institutions to apply.

Application Due Date: June 6, 2023

Cancer Health Equity Research Centers at Minority-Serving Institutions

RFA: Cancer Health Equity Research Centers at Minority-Serving Institutions

Sponsor: American Cancer Society (ACS)

Abstract: This funding is intended to support the formation of Cancer Health Equity Research Centers (CHERCs) designed to target cancer health disparities that are unique to a local or regional community. We anticipate this funding will stimulate novel collaborations and approaches to mitigate societal risk factors and contribute to our goals for achieving health equity and reducing cancer mortality.

LOI Due Date: May 16, 2023

Application Due Date: October 15, 2023

Notice of Special Interest: Telehealth in Cancer

NOT-CA-21-04

Sponsor: National Cancer Institute (NCI); United States Department of Health and Human Service (HHS)

Abstract: The purpose of this Notice of Special Interest (NOSI) is to highlight the interest of the NCI’s Division of Cancer Control and Population Sciences in receiving investigator-initiated applications for conducting research on the use of telehealth in cancer-related care. Studies focused on populations that experience inequities in access to care and have worse cancer outcomes compared to the general population are strongly encouraged. This NOSI for R01 and R21 applications is a companion announcement to the RFA titled “Centers on Telehealth Research and Cancer-Related Care” (RFA-CA-21-029).

Application Due Date: March 8, 2024

Notice of Special Interest (NOSI): Expanding Cancer Control Research in Persistent Poverty Areas

Sponsor: National Institutes of Health (NIH); United States Department of Health and Human Services (HHS)

Abstract: The purpose of this Notice is to inform potential applicants about the National Cancer Institute (NCI)’s special interest in providing resources to support highly collaborative, multi-disciplinary Program Projects (P01s) that focus on the development and conduct of cancer control research in low-income and/or underserved populations living in persistent poverty (PP) areas. NCI is interested in programs that address the challenges and opportunities related to working in partnership with local clinics and other health or public health-related organizations to enhance the prevention of cancer and delivery of cancer care strategies to reduce the burden of cancer in PP areas.

Application Due Date: May 7, 2023

Notice of Special Interest: National Cancer Institute Administrative Supplement Opportunity for Strategies to Optimize Recruitment and Retention of Cancer Prevention and Symptom Management Clinical Trial Participants

NOT-CA-21-070

Sponsor: National Cancer Institute (NCI)

Abstract: This Notice of Special Interest informs current awardees of National Cancer Institute (NCI) cancer prevention and symptom management clinical trial grants of an opportunity for supplemental funding of eligible NCI-supported grant and cooperative agreement awards so that awardees can undertake and evaluate recruitment and retention strategies and thereby facilitate the success of their clinical trial programs.

Application Due Date: May 15, 2023